BC Platforms
BC Platforms is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
A single-arm, multi-centre trial to evaluate efficacy and safety of imlifidase in highly sensitised children (1-17 years) receiving a kidney transplant with positive crossmatch against a living or deceased donor converted to negative after imlifidase treatment
Sponsor Hansa Biopharma AB
- Start (EU)
- Latest update
- Estimated end
A prospective, post-authorisation long-term follow up trial of patients previously treated with imlifidase prior to kidney transplantation, including a non-comparative concurrent reference cohort
Sponsor Hansa Biopharma AB
- Start (EU)
- Latest update
- Estimated end
A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in the treatment of severe anti-GBM antibody disease (Goodpasture disease)
Sponsor Hansa Biopharma AB
- Start (EU)
- Latest update
- Estimated end
DiaPrecise, A Phase II Open Label Study to evaluate the safety and feasibility of intralymphatic administration of Diamyd® in individuals at risk for Type 1 diabetes carrying the HLA DR3-DQ2 haplotype
Sponsor Diamyd Medical AB
- Start (EU)
- Latest update
- Estimated end
- Not reported
A controlled, open-label post-authorisation efficacy and safety study in imlifidase desensitised kidney transplant patients with positive crossmatch against a deceased donor prior to imlifidase treatment, including non-comparative registry and concurrent reference cohorts
Sponsor Hansa Biopharma AB
- Start (EU)
- Latest update
- Estimated end
(ESMERALD) A phase-2A, single-centre, prospective, uncontrolled, open label, single arm, exploratory clinical study to evaluate the safety and efficacy of cutaneous AUP1602-C with foam dressing as a treatment for non-healing neuroischemic diabetic foot ulcers
Sponsor Aurealis Oy
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A phase-2, multi-centre, prospective, randomized, standard-of-care plus placebo-controlled, patient and central evaluator blinded, parallel arm, clinical study to evaluate safety, tolerability and efficacy of the recommended phase-2 dose of AUP1602-C in two dosing frequencies as a topical treatment for non-healing neuro-ischemic diabetic foot ulcers
Sponsor Aurealis Oy
- Start (EU)
- Latest update
- Estimated end
- Not reported
An open-label phase 1b/2 study assessing the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma
Sponsor Alligator Bioscience AB
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for BC Platforms?
The 2026-10-09 snapshot links BC Platforms to 8 distinct CTIS trials. Recorded services include Data management, Statistical analysis, Data management for safety aggregate reports, Electronic data capture, among 7 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for BC Platforms?
The most frequently recorded therapeutic areas are Nephrology, Transplantation. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to BC Platforms conducted?
The linked trials record locations in 14 countries, including Italy, Spain, France, Sweden, Belgium. These are trial locations, not confirmed office locations or countries where BC Platforms delivered services.
What can this page tell me about BC Platforms's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under BC Platforms. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- BC Platforms AB